Management ChangeJun 22, 2026, 08:02 AM
Revolution Medicines R&D President Kelsey to Retire
AI Summary
Revolution Medicines announced that Dr. Steve Kelsey, President of Research and Development, will retire effective January 4, 2027, transitioning to a new role as Senior Advisor to the CEO on July 1, 2026. The company also held its Annual Meeting, where stockholders elected two Class III directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved executive compensation on a non-binding, advisory basis.
Key Highlights
- Dr. Steve Kelsey to retire as President, R&D, effective January 4, 2027.
- Dr. Kelsey will transition to Senior Advisor to CEO on July 1, 2026.
- Company contemplates appointing Dr. Kelsey to the Board of Directors post-retirement.
- Stockholders elected Alexis Borisy and Mark A. Goldsmith as Class III directors.
- PricewaterhouseCoopers LLP ratified as independent auditor with 181,309,783 votes For.
- Executive officer compensation approved on advisory basis with 155,110,825 votes For.
Price Impact
More from RVMD